These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 28730728)

  • 21. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
    J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
    Tanday N; Irwin N; Moffett RC; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2020 Dec; 22(12):2468-2478. PubMed ID: 32844576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice.
    Irwin N; Frizelle P; O'Harte FP; Flatt PR
    J Endocrinol; 2013 Jan; 216(1):53-9. PubMed ID: 23055535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
    Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
    Irwin N; Montgomery IA; O'Harte FP; Frizelle P; Flatt PR
    Int J Obes (Lond); 2013 Aug; 37(8):1058-63. PubMed ID: 23164696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.
    Gao H; Zhao Q; Li K; Qin F; Yin X; Lu Z; Song Z; Wu Y; Shen Y; Pan Y; Jin L; Yanfeng Zhang
    Exp Cell Res; 2021 Feb; 399(1):112454. PubMed ID: 33359447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
    Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
    O'Harte FP; Franklin ZJ; Irwin N
    Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
    Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR
    Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esculentin-2CHa-Related Peptides Modulate Islet Cell Function and Improve Glucose Tolerance in Mice with Diet-Induced Obesity and Insulin Resistance.
    Ojo OO; Srinivasan DK; Owolabi BO; Vasu S; Conlon JM; Flatt PR; Abdel-Wahab YH
    PLoS One; 2015; 10(10):e0141549. PubMed ID: 26512980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
    Pathak V; Gault VA; Flatt PR; Irwin N
    Mol Cell Endocrinol; 2015 Feb; 401():120-9. PubMed ID: 25449420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exenatide and weight loss.
    Bradley DP; Kulstad R; Schoeller DA
    Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
    Mietlicki-Baase EG; Liberini CG; Workinger JL; Bonaccorso RL; Borner T; Reiner DJ; Koch-Laskowski K; McGrath LE; Lhamo R; Stein LM; De Jonghe BC; Holz GG; Roth CL; Doyle RP; Hayes MR
    Diabetes Obes Metab; 2018 May; 20(5):1223-1234. PubMed ID: 29327400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.